March 18, 2026

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

Conexiant

March 17, 2026

Obesity Medications Get New Guidance

Panel outlines pharmacotherapy roles across obesity complications and long-term weight management.

Conexiant

March 09, 2026

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

Conexiant

February 18, 2026

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Conexiant

February 11, 2026

AMA Backs Structured Vaccine Review

Medical societies and public health groups will collaborate on policy questions and evidence briefs for the 2026 to 2027 respiratory virus season.

Conexiant

January 27, 2026

The Exam Room Is Listening Now

As AI quietly enters exam rooms, physicians report real relief—and real concerns about accuracy, trust, and control.

KFF Health News

December 22, 2025

FDA Approves New Treatment for Lung Fibrosis

Nerandomilast becomes first preferential PDE4B inhibitor approved for PPF, slowing FVC decline in phase 3 trial

Conexiant

December 05, 2025

Fancy Gadgets, Higher Bills: HSA Era

Republican proposals to expand health savings accounts amid expiring ACA subsidies outline potential shifts in coverage costs and limitations in how patients may use HSA funds.

KFF Health News

December 03, 2025

Ranitidine’s return 'unlikely to provide greater clinical benefit'

New formulation incorporates stronger manufacturing controls and stability measures to prevent NDMA from forming.

Conexiant

November 26, 2025

FDA Grants Accelerated Approval of Voyxact

The subcutaneous injection offers a new option for adults at risk of progression to kidney failure.

Conexiant